SCHEMBL1769324

SCHEMBL1769324

N#CC1(c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.46
SCD O00767 1/20 0.44
ALDH1A1 P00352 2/20 0.41
ACHE P22303 1/20 0.41
HSD17B10 Q99714 1/20 0.41
OPRM1 P35372 3/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
MMP14 P50281 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
VCAM1 P19320 1/20 0.39
SIRT6 Q8N6T7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3047350 0.93 PGR (0.43) PGRSCDALDH1A1ACHEHSD17B10
SCHEMBL2814643 0.93 ALDH1A1 (0.44) PGRSCDALDH1A1ACHEHSD17B10
SCHEMBL2815633 0.91 ALDH1A1 (0.43) PGRSCDALDH1A1OPRM1MEN1
SCHEMBL3897910 0.89 L3MBTL1 (0.44) PGRSCDALDH1A1MAPTLMNA
SCHEMBL2876866 0.89 PDE4A (0.41) PGRSCDALDH1A1ACHEHSD17B10
SCHEMBL521393 0.89 ADRB1 (0.44) PGRSCDOPRM1VCAM1SIRT6
SCHEMBL5475184 0.87 SCD (0.42) PGRSCDALDH1A1OPRM1MEN1
SCHEMBL24992890 0.81 ALDH1A1 (0.44) SCDALDH1A1OPRM1MEN1MAPT
SCHEMBL3909759 0.81 CA12 (0.46) SCDALDH1A1OPRM1MAPTLMNA
SCHEMBL3901907 0.81 ALDH1A1 (0.52) SCDALDH1A1OPRM1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243169-A1 PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL-HETEROCYCLES OR ARENES SYNGENTA CROP PROTECTION AG (CH) 2025-07-31 US disclosed
EP-4504706-A1 PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL - HETEROARENES OR ARENES Syngenta Crop Protection AG (CH) 2025-02-12 EP disclosed
CN-119032081-A Process for preparing various substituted cyanocyclopropyl-heteroarenes or arenes 先正达农作物保护股份公司 2024-11-26 CN disclosed
WO-2023194496-A1 PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL - HETEROARENES OR ARENES SYNGENTA CROP PROTECTION AG (CH) 2023-10-12 WO disclosed
WO-2023194496-A1 PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL - HETEROARENES OR ARENES SYNGENTA CROP PROTECTION AG (CH) 2023-10-12 WO disclosed
US-11084784-B2 ROR-gamma modulators and uses thereof Piramal Enterprises Limited (IN) 2021-08-10 US disclosed
WO-2021078995-A1 SELECTIVE POLYPEPTIDE SYNTHESIS STALLING ASSAY AND COMPOUND UMC UTRECHT HOLDING B.V. (NL) 2021-04-29 WO disclosed
EP-3811945-A1 COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS UMC Utrecht Holding B.V. (NL) 2021-04-28 EP disclosed
US-20180215707-A1 ROR-GAMMA MODULATORS AND USES THEREOF Piramal Enterprises Limited (IN) 2018-08-02 US disclosed
EP-3122721-A1 ROR-GAMMA MODULATORS AND USES THEREOF Piramal Enterprises Limited (IN) 2017-02-01 EP disclosed
EP-1448536-A1 CYCLOPROPYL-CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2004-08-25 EP disclosed
US-6686363-B2 EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA KYORIN PHARMACEUTICAL CO., LTD. (JP) 2004-02-03 US disclosed
WO-2004007458-A1 SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF AMGEN INC. (US) 2004-01-22 WO disclosed
WO-2004007457-A2 SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2004-01-22 WO disclosed
WO-2004007481-A2 SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS AMGEN INC. (US) 2004-01-22 WO disclosed
US-20030225106-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-12-04 US disclosed
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK SHARP & DOHME CORP. 2003-12-04 US disclosed
US-20030203922-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-30 US disclosed
US-20030134836-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2003-07-17 US disclosed
WO-2003048136-A1 CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225106-A1 Substituted alkylamine derivatives and methods of use NAT1, PIGO, AADAC PGR 1096/4885SCD 1230/4885ALDH1A1 389/4885
US-20250243169-A1 PROCESS FOR THE PREPARATION OF DIVERSELY SUBSTITUTED CYANOCYCLOPROPYL-HETEROCYCLES OR ARENES CYCS, CCNE1, CCNT1 PGR 618/4885SCD 4130/4885ALDH1A1 804/4885
US-11084784-B2 ROR-gamma modulators and uses thereof RORB, RORA, RORC PGR 1899/4885SCD 1274/4885ALDH1A1 902/4885
US-20030134836-A1 Substituted arylamine derivatives and methods of use NAT1, AADAC, AHR PGR 222/4885SCD 1927/4885ALDH1A1 178/4885
US-20030203922-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 PGR 801/4885SCD 1897/4885ALDH1A1 192/4885
US-20180215707-A1 ROR-GAMMA MODULATORS AND USES THEREOF RORB, RORA, RORC PGR 1899/4885SCD 1274/4885ALDH1A1 902/4885
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF ALAD, OXA1L, ECI1 PGR 3575/4885SCD 328/4885ALDH1A1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.